Table 4 Variables related to 21-hydroxylase deficiency according to phenotype
From: Cardiovascular risk in Cuban adolescents and young adults with congenital adrenal hyperplasia
Phenotype | p- value | |||
|---|---|---|---|---|
SW n = 8 | SV n = 5 | NC n = 9 | ||
Age at diagnosis (years) | 0.01 (0.01–1) | 1 (0.01–8) | 12 (6–18) | < 0.01 |
Time since diagnosis (years) | 14 (10–31) | 11 (10–25) | 8 (0.8–12) | < 0.01 |
Hydrocortisone equivalent dose mg/d | 37.5 (15–40) | 27.5 (15–50) | 15 (15–17.5) | 0.10 |
Hydrocortisone equivalent dose (mg/m2/d) | 20 (12.9–27.1) | 17.8 (7.5–31.4) | 8.7 (8.7–10.6) | 0.07 |
Testosterone (nmol/L) | 2.9 (0.5–6.4) F 4.0 M | 4.2 (1.1–9.2) F 7.0 (0.8–13.1) M | 2.9 (0.5–6.4) F 4.0 M | 0.91 |
17OHP (ng/mL) | 12.4 (3.1–14) | 13 (1.5–13.2) | 2.4 (0.3–13) | 0.03 |
CIMT (mm) | 0.46 (0.4–0.55) | 0.41(0.3–0.5) | 0.52 (0.45–0.6)a | 0.05 |
FMD (%) | 9.65 (0.0–17.96) | 11.55 (4.29–19.47) | 10.91 (2.61–19.85)a | 0.84 |
Epicardial fat (mm) | 1.44 (0.0–5.8) | 0.62 (0.0–1.1) | 1.14 (0.0–5.0) | 0.82 |